paclitaxel liposome + carboplatin + PD-1 monoclonal antibody

This is a combination regimen consisting of three agents: - **Paclitaxel liposome** is a nanoparticle (liposomal) formulation of the chemotherapy drug paclitaxel, which stabilizes microtubules and inhibits cell division. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **PD-1 monoclonal antibody** refers to an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) on T-cells. By blocking PD-1, these antibodies (such as pembrolizumab or nivolumab) enhance the immune system's ability to recognize and destroy cancer cells. The combination leverages both cytotoxic effects from chemotherapy and immunomodulatory effects from checkpoint inhibition. This regimen has been studied in various cancers including non-small cell lung cancer, endometrial carcinoma, and breast cancer—most commonly with pembrolizumab as the PD-1 inhibitor[2][4][5][7]. The use of a *liposomal* formulation of paclitaxel may offer improved pharmacokinetics or reduced toxicity compared to conventional formulations.

Other names

paclitaxel liposome plus carboplatin plus PD-1 monoclonal antibodypaclitaxel liposome/carboplatin/PD-1 inhibitor combination